Eloxx Pharmaceuticals, Inc. (ELOX)
Stock Price:
$3.03 USD
0.23 (8.21%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
121.62M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-46.34M |
| Shares Out |
40.14M |
| EPS (ttm) |
-1.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$3.03 |
| Previous Close |
$2.80 |
| Change ($) |
0.23 |
| Change (%) |
8.21% |
| Day's Open |
2.84 |
| Day's Range |
2.72 - 3.05 |
| Day's Volume |
61,223 |
| 52-Week Range |
1.44 - 8.16 |
More Stats
| Market Cap |
121.62M |
| Enterprise Value |
99.79M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
40.14M |
| Float |
23.36M |
| EPS (basic) |
-1.16 |
| EPS (diluted) |
-1.16 |
| FCF / Share |
-0.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.42M |
| Short Ratio |
30.56 |
| Short % of Float |
6.07% |
| Beta |
2.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.84 |
| Revenue |
n/a |
| Operating Income |
-45.62M |
| Net Income |
-46.34M |
| Free Cash Flow |
-38.84M |
| Net Cash |
21.83M |
| Net Cash / Share |
0.54 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-43.74% |
| ROE |
-122.73% |
| ROIC |
-141.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$4.75*
(56.77% upside)
Low
3.00
Current: $3.03
High
6.00
Target: 4.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | 0.10 | - | 0.20 | - | 0.14 |
| Gross Profit | - | - | - | - | - | 0.10 | - | 0.20 | - | 0.14 |
| Operating Income | -50.56 | -47.57 | -20.39 | -9.84 | -6.28 | -9.15 | -4.65 | -5.41 | -7.92 | -4.85 |
| Net Income | -50.87 | -47.19 | -21.21 | -9.85 | -6.41 | -9.23 | -6.12 | -5.07 | -7.27 | -13.38 |
| Shares Outstanding | 38.06 | 32.44 | 4.98 | 4.21 | 4.15 | 0.27 | 0.07 | 0.04 | 0.03 | 0.01 |
| Earnings Per Share | -1.34 | -1.45 | -4.75 | -2.60 | -1.67 | -50.60 | -102.20 | -156.20 | -280.00 | -1,340.00 |
| Operating Cash Flow | -39.39 | -31.37 | -15.94 | -8.84 | -5.74 | -4.87 | -3.90 | -4.39 | -5.39 | -4.74 |
| Capital Expenditures | -0.04 | -0.23 | -0.24 | -0.04 | -0.01 | -0.63 | -0.53 | -0.45 | -0.69 | -0.81 |
| Free Cash Flow | -39.43 | -31.60 | -16.17 | -8.88 | -5.75 | -5.50 | -4.43 | -4.84 | -6.08 | -5.55 |
| Cash & Equivalents | 56.32 | 48.65 | 24.15 | 2.25 | 2.37 | 6.11 | 1.60 | 2.00 | 3.61 | 8.03 |
| Total Debt | 16.17 | - | - | - | - | - | 2.19 | 2.20 | 2.20 | 2.19 |
| Net Cash / Debt | 40.15 | 48.65 | 24.15 | 2.25 | 2.37 | 6.11 | -0.58 | -0.20 | 1.41 | 5.83 |
| Assets | 58.95 | 50.72 | 24.78 | 3.13 | 15.64 | 33.33 | 7.10 | 6.95 | 8.60 | 13.91 |
| Liabilities | 22.73 | 7.81 | 3.42 | 2.52 | 6.92 | 5.84 | 3.31 | 3.50 | 4.08 | 5.93 |
| Book Value | 36.21 | 42.91 | 21.36 | 0.61 | 8.72 | 27.49 | 3.79 | 3.45 | 4.52 | 7.98 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Eloxx Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
29 |
| CEO |
Gregory C. Williams |
Stock Information
| Ticker Symbol |
ELOX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ELOX |
Description
Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.